UNSPSC 51182064: Prasterone sodium sulfate

This classification denotes a therapeutic androgen with the molecular structure C19H27O5S.NA.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, E1CR8487EN chemically known as androst-5-en-17-one, 3.beta.-hydroxy-, hydrogen sulfate, sodium salt, dihydrate, but more commonly known as prasterone sodium sulfate, which bears US NIH Compound Identifier 14193. European Medicines Agency schedules Prasterone sodium sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04010MIG.

Most nations, for tariff and trade purposes, schedule prasterone sodium sulfate under HS 29372900. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)[O-])C.[NA+].

UNSPSC 51182064 Prasterone sodium sulfate, a Commodity code, covers a pharmaceutical active ingredient with limited recent activity in state and local procurement. The code nominally designates prasterone sodium sulfate, a pharmaceutical compound sometimes used in therapeutic formulations, but the source does not identify concrete recent state or local solicitations, purchasing patterns, or issuing bodies acquiring this material at the state or local level. State and local governments do not typically procure pharmaceutical active ingredients directly; such materials flow through authorized pharmaceutical distributors, hospital pharmacy systems, or state Medicaid agencies as finished medications rather than as raw chemical ingredients. The UNSPSC code structure includes this commodity designation for completeness in hospital and clinical procurement systems, but demand signals for the raw ingredient itself from state and local buyers appear minimal or absent in current public solicitations.

No recent state and local contract opportunities under this code are present in the source. If procurement activity exists, it occurs through private vendor relationships, closed state pharmacy procurement channels, or does not appear in the public RFP/RFQ/IFB/ITB record. Business development professionals should treat this code as having negligible current pursuit potential unless they hold direct relationships with state Medicaid agencies, state hospital systems, or institutional pharmacy groups that source active pharmaceutical ingredients outside the public notice channel.